Sclerostin is a direct target of osteoblast-specific transcription factor osterix

Biochemical and Biophysical Research Communications

Volumn 400, Issue 4, 2010, Pages 684-688

  Yang, Fan ^a   Tang, Wanjin ^a   So, Sarah ^a   de Crombrugghe, Benoit ^b   Zhang, Chi ^a,c  

^a TEXAS SCOTTISH RITE HOSPITAL FOR CHILDREN   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bone formation; Osteoblast; Osx; Sost; Wnt signaling

Indexed keywords

CYTOSINE; GUANINE; SCLEROSTIN; TRANSCRIPTION FACTOR OSTERIX; WNT PROTEIN;

ARTICLE; ASSAY; BINDING SITE; CALVARIA; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; DELETION MUTANT; DOSE RESPONSE; DOWN REGULATION; EMBRYO; FEEDBACK SYSTEM; GEL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPOTHESIS; IMMUNOPRECIPITATION; KNOCKOUT MOUSE; MESENCHYME CELL; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; TRANSIENT TRANSFECTION; UPREGULATION;

ANIMALS; BINDING SITES; BONE MORPHOGENETIC PROTEINS; CELL LINE; DOWN-REGULATION; GENETIC MARKERS; HUMANS; MICE; MICE, MUTANT STRAINS; OSTEOBLASTS; PROMOTER REGIONS, GENETIC; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

MUS;

EID: 77957265982     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.08.128     Document Type: Article

References (25)

1. Franceschi R.T., Ge C., Xiao G., Roca H., Jiang D. Transcriptional regulation of osteoblasts. Cells Tissues Organs 2009, 189:144-152.
2. Nakashima K., Zhou X., Kunkel G., Zhang Z., Deng J.M., Behringer R.R., de Crombrugghe B. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002, 108:17-29.
3. St-Jacques B., Hammerschmidt M., McMahon A.P. Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev. 1999, 13:2072-2086.
4. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., Shimizu Y., Bronson R.T., Gao Y.H., Inada M., Sato M., Okamoto R., Kitamura Y., Yoshiki S., Kishimoto T. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764.
5. Piters E., Boudin E., Van Hul W. Wnt signaling: a win for bone. Arch. Biochem. Biophys. 2008, 473:112-116.
6. Baron R., Rawadi G., Roman-Roman S. Wnt signaling: a key regulator of bone mass. Curr. Top. Dev. Biol. 2006, 76:103-127.
7. Little R.D., Carulli J.P., Del Mastro R.G., Dupuis J., Osborne M., Folz C., Manning S.P., Swain P.M., Zhao S.C., Eustace B., Lappe M.M., Spitzer L., Zweier S., Braunschweiger K., Benchekroun Y., Hu X., Adair R., Chee L., FitzGerald M.G., Tulig C., Caruso A., Tzellas N., Bawa A., Franklin B., McGuire S., Nogues X., Gong G., Allen K.M., Anisowicz A., Morales A.J., Lomedico P.T., Recker S.M., Van Eerdewegh P., Recker R.R., Johnson M.L. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 2002, 70:11-19.
8. Babij P., Zhao W., Small C., Kharode Y., Yaworsky P.J., Bouxsein M.L., Reddy P.S., Bodine P.V., Robinson J.A., Bhat B., Marzolf J., Moran R.A., Bex F. High bone mass in mice expressing a mutant LRP5 gene. J. Bone Miner. Res. 2003, 18:960-974.
9. Day T.F., Guo X., Garrett-Beal L., Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev. Cell 2005, 8:739-750.
10. Hill T.P., Spater D., Taketo M.M., Birchmeier W., Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev. Cell 2005, 8:727-738.
11. Hu H., Hilton M.J., Tu X., Yu K., Ornitz D.M., Long F. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 2005, 132:49-60.
12. Rodda S.J., McMahon A.P. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 2006, 133:3231-3244.
13. Balemans W., Piters E., Cleiren E., Ai M., Van Wesenbeeck L., Warman M.L., Van Hul W. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcif. Tissue Int. 2008, 82:445-453.
14. Semenov M., Tamai K., He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem. 2005, 280:26770-26775.
15. ten Dijke P., Krause C., de Gorter D.J., Lowik C.W., van Bezooijen R.L. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J. Bone Joint Surg. Am. 2008, 90(Suppl. 1):31-35.
16. Winkler D.G., Sutherland M.K., Geoghegan J.C., Yu C., Hayes T., Skonier J.E., Shpektor D., Jonas M., Kovacevich B.R., Staehling-Hampton K., Appleby M., Brunkow M.E., Latham J.A. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003, 22:6267-6276.
17. Zhang C., Cho K., Huang Y., Lyons J.P., Zhou X., Sinha K., McCrea P.D., de Crombrugghe B. Inhibition of Wnt signaling by the osteoblast-specific transcription factor Osterix. Proc. Natl. Acad. Sci. USA 2008, 105:6936-6941.
18. Zhang C., Baudino T.A., Dowd D.R., Tokumaru H., Wang W., MacDonald P.N. Ternary complexes and cooperative interplay between NCoA-62/Ski-interacting protein and steroid receptor coactivators in vitamin D receptor-mediated transcription. J. Biol. Chem. 2001, 276:40614-40620.
19. Zhang C., Dowd D.R., Staal A., Gu C., Lian J.B., van Wijnen A.J., Stein G.S., MacDonald P.N. Nuclear coactivator-62 kDa/Ski-interacting protein is a nuclear matrix-associated coactivator that may couple vitamin D receptor-mediated transcription and RNA splicing. J. Biol. Chem. 2003, 278:35325-35336.
20. Issack P.S., Helfet D.L., Lane J.M. Role of Wnt signaling in bone remodeling and repair. HSS J. 2008, 4:66-70.
21. Krishnan V., Bryant H.U., Macdougald O.A. Regulation of bone mass by Wnt signaling. J. Clin. Invest. 2006, 116:1202-1209.
22. Wergedal J.E., Veskovic K., Hellan M., Nyght C., Balemans W., Libanati C., Vanhoenacker F.M., Tan J., Baylink D.J., Van Hul W. Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J. Clin. Endocrinol. Metab. 2003, 88:5778-5783.
23. Lin C., Jiang X., Dai Z., Guo X., Weng T., Wang J., Li Y., Feng G., Gao X., He L. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J. Bone Miner. Res. 2009, 24:1651-1661.
24. Keller H., Kneissel M. SOST is a target gene for PTH in bone. Bone 2005, 37:148-158.
25. van Bezooijen R.L., Roelen B.A., Visser A., van der Wee-Pals L., de Wilt E., Karperien M., Hamersma H., Papapoulos S.E., ten Dijke P., Lowik C.W. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 2004, 199:805-814.